Our analysis indicates that Alternative Funding Programs which exclude specialty drugs from coverage and then use Patient Assistance Programs for funding are exposing employers and employees to ERISA and IRS risks and violations. More importantly it is likely a violation of fiduciary responsibility for self-funded plans. See the details of the analysis below.

As a Public Benefit Company with a mission of ensuring that every patient is on an effective therapy at a fair market cost, we believe that regulatory agencies such as the FTC and DOJ have a responsibility to break up the structural monopolies that PBMs, Provider Systems and Health plans have created. These monopolies have resulted in 4% of the world’s population, who are Americans, paying 49% of global healthcare costs. Please click on the link if you would like a copy of VIVIO’s comments to the FTC on PBM Practices and how to regulate them.

Pramod John, CEO, and Bhargav Raman, M.D., director, clinical product, at VIVIO Health, discuss how their system can match patients to therapies based on data rather than a formulary.

As a Public Benefit Company with a mission of ensuring that every patient is on an effective therapy at a fair market cost, we are thrilled to announce that Marcus Osborne has joined our Advisory Board to help us get there. Marcus has a passion for working on big problems and there is no bigger problem than the waste of billions on therapies that don’t work and often harm patients.

Marcus previously served as Senior Vice President of Health Transformation at Walmart where he was focused on furthering Walmart’s goal of improving the healthcare industry in the U.S. by increasing access and affordability in the system for consumers, helping to launch Walmart Health and other key health initiatives.  Prior to joining Walmart in 2007, Osborne served as the Chief Financial Officer of the Clinton Foundation Health Access Initiative, helping increase access to HIV/AIDS treatment in the developing world, and as a Senior Management Consultant for Alliance Consulting Group in Boston, Massachusetts. He attended the Harvard Business School and received his Masters in Business Administration, graduating with honors.

Trials designs often don’t tell us what we want to know, is A better than B? Check out this article from VIVIO team member Bishal Gyawali et. al. on the gaming of metastatic prostate cancer drug trials. The Medpage article has a link to the article.

Relentless Health Value host Stacey Richter talks with with Pramod John about drug formularies and rebates and why focusing on actual patient outcomes leads to broader access and lower costs.

Relentless Health Value host Stacey Richter talks with with Pramod John about the reality of specialty drugs and what the terms efficacy and effectiveness really mean because they might not mean what you think they mean.

Healthcare Upside/Down: Host Nick van Terheyden, MD talks with with Pramod John, CEO of VIVIO about drug pricing. Drug pricing is outstripping our ability to pay, and a large portion of these escalating costs is linked to specialty drugs that can account for as much as 50% of costs while only treating a small percentage of patients.

Apparently the often-low standards for the FDA aren’t low enough. Now we just move trials to poor countries and use control arms that we wouldn’t approve here. VIVIO team member Bishal Gyawali writes about this in the Lancet. Look at the data yourselves and stop listening to the ‘experts’ who are paid to say ‘yes.’

Interview about our mission with our CEO Pramod John